ArticleFrontiers in neurology2018
Method of Levodopa Response Calculation Determines Strength of Association With Clinical Factors in Parkinson Disease.
Article in Frontiers in neurology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.
- Dopaminergic responsiveness and dopaminergic challenge tests of Parkinson's disease: a systematic review and meta-analysis.Journal of neurology · 2025Pooled it
- Rapid Progression and Shorter Survival in Indians Affected with Probable MSA: A Prospective Cohort Study.Movement disorders clinical practice · 2025Article
- Investigation of the voice handicaps in Parkinson's disease and determination of the clinical correlates.Journal of neural transmission (Vienna, Austria : 1996) · 2025Article
- Automatic speech analysis combined with machine learning reliably predicts the motor state in people with Parkinson's disease.NPJ Parkinson's disease · 2025Article
- Detailed investigation of the levodopa response rates in distinct motor subscores in Parkinson's disease patients with and without STN-DBS.Neurodegenerative disease management · 2025Article
- Investigation of nonmotor symptoms and their clinical correlates in patients with Parkinson's disease.Neurodegenerative disease management · 2025Article
- Machine learning models for the prediction of levodopa response to tremor in Parkinson's disease.Frontiers in aging neuroscience · 2025Article
- Prosody matters: Preserved prominence marking strategies in people with Parkinson's disease independent of motor status.PloS one · 2024Article
- Long-term follow-up of Parkinsonian patients operated on with deep brain electromodulation without intraoperative microrecording.Surgical neurology international · 2023Article
- Non-Contact Hand Movement Analysis for Optimal Configuration of Smart Sensors to Capture Parkinson's Disease Hand Tremor.Sensors (Basel, Switzerland) · 2022Article
- Multivariate genomic and transcriptomic determinants of imaging-derived personalized therapeutic needs in Parkinson's disease.Scientific reports · 2022Article
- Istradefylline Versus Opicapone for "Off" Episodes in Parkinson's Disease: A Systematic Review and Meta-Analysis.Annals of neurosciences · 2021Article
- Detecting Effect of Levodopa in Parkinson's Disease Patients Using Sustained Phonemes.IEEE journal of translational engineering in health and medicine · 2021Article
- Prediction of the Levodopa Challenge Test in Parkinson's Disease Using Data from a Wrist-Worn Sensor.Sensors (Basel, Switzerland) · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe levodopa challenge test is routinely used in Parkinson disease (PD) to determine a patient's motor improvement following levodopa administration [levodopa response (LR)]. LR is most commonly reported as a percent OFF to ON change in the Unified Parkinson Disease Rating Scale (UPDRS) part III score, and occasionally as an absolute difference in score. This inconsistency in LR determination alters how clinical factors such as patient age and disease duration are understood in relation to LR in PD.
objectiveThe aim of this study was to compare the calculation of the LR as either a percent change or difference in UPDRS-III motor score between OFF and ON medication. These two scores were then used to correlate to disease duration, patient age, levodopa duration, levodopa equivalent dose (LED), OFF score, cognition, mood, gait, and quality of life (QOL).
methods70 PD patients underwent the levodopa challenge test. The UPDRS-III motor examination was performed in the defined OFF and ON medication states to determine LR. Each patient was assessed after 12-14 h without anti-parkinsonian medication and then given three 100/25 mg levodopa/carbidopa tablets. LR was reported as both a difference in score [OFF - ON; absolute LR (aLR)] and as a percent change in score [(OFF - ON)/OFF*100%; %LR]. Patients completed the following non-motor symptom assessment scales: Montreal Cognitive Assessment, Freezing of Gait Questionnaire, Activities-specific Balance Confidence Scale, Parkinson's Disease Questionnaire, and Geriatric Depression Scale. The effect of the LR calculation method was correlated to the clinical measures.
resultsThe aLR was significantly associated with disease duration (
conclusionAlthough the %LR is more commonly employed in clinical protocols and research studies, the aLR is the superior method for reporting motor response to levodopa in PD given its significant associations with the clinical factors evaluated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.